Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 18/20 | 0.39 |
| ▸ | CA2 | P00918 | 18/20 | 0.39 |
| ▸ | CA4 | P22748 | 11/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2597556 | 0.87 | TDP1 (0.44) | TDP1KDM4ELMNACHRM2ADRA2A | |
| SCHEMBL7367941 | 0.82 | KCNH2 (0.51) | TDP1KDM4ELMNACHRM2ADRA2A | |
| SCHEMBL1230833 | 0.80 | HSD17B10 (0.39) | TDP1KDM4ELMNACHRM2ADRA2A | |
| SCHEMBL5553832 | 0.79 | CA1 (0.46) | CA1CA2CA4CA12CA9 | |
| Pentetic Acid SCHEMBL9440802 | 0.79 | TDP1 (0.65) | TDP1KDM4ELMNACHRM2ADRA2A | |
| SCHEMBL2057057 | 0.78 | NR1D1 (0.36) | CA1CA2CA4 | |
| SCHEMBL9878685 | 0.76 | TDP1 (0.52) | TDP1KDM4ELMNACHRM2ADRA2A | |
| SCHEMBL16113686 | 0.74 | TDP1 (0.58) | TDP1KDM4ELMNACHRM2ADRA2A | |
| SCHEMBL7512416 | 0.70 | CA1 (0.71) | CA1CA2CA4CA12CA9 | |
| SCHEMBL8425241 | 0.70 | MAPT (0.48) | TDP1KDM4ELMNACHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402586-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-22 | — | — | US | claimed |
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-09-21 | — | — | US | claimed |
| US-7029654-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | claimed |
| EP-0766968-B1 | Diagnostic imaging agent | NIHON MEDIPHYSICS CO LTD (JP) | 2001-01-17 | — | — | EP | claimed |
| EP-0766968-A1 | Diagnostic imaging agent | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1997-04-09 | — | — | EP | claimed |
| EP-2408930-B1 | BIOTINIDASE ASSAY | WALLAC OY (FI) | 2015-05-06 | — | — | EP | disclosed |
| US-8597903-B2 | Biotinidase assay | WALLAC OY (FI) | 2013-12-03 | — | — | US | disclosed |
| US-20120045784-A1 | BIOTINIDASE ASSAY | Joachim Ngiamas trustee for Joachim Ngiam Trust Fund ABN | 2012-02-23 | — | — | US | disclosed |
| US-7829584-B2 | Pyridines and pyridine N-oxides as modulators of thrombin | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-09 | — | — | US | disclosed |
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7550474-B2 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICALS RESEARCH & DEVELOPMENT, L.L.C. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1613319-B1 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-5342604-A | Bone disorders | THE DOW CHEMICAL COMPANY (US) | 1994-08-30 | — | — | US | disclosed |
| US-5271929-A | Nuclear magnetic resonance imaging agent comprising a di-aldehyde complex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1993-12-21 | — | — | US | disclosed |
| EP-0570022-A2 | Chelants possessing ortho ligating functionality and complexes thereof | THE DOW CHEMICAL COMPANY (US) | 1993-11-18 | — | — | EP | disclosed |
| EP-0566166-A1 | Chelants possessing ortho ligating functionality and complexes thereof | THE DOW CHEMICAL COMPANY (a Delaware corporation) (US) | 1993-10-20 | — | — | EP | disclosed |
| EP-0523572-A1 | Nuclear magnetic resonance imaging agent | NIHON MEDI-PHYSICS CO., LTD. (JP) | 1993-01-20 | — | — | EP | disclosed |
| US-5006643-A | Reacting aminofunctional chelates with thiophosgene | THE DOW CHEMICAL COMPANY (US) | 1991-04-09 | — | — | US | disclosed |
| WO-1990007342-A1 | PROCESS FOR PREPARING ISOTHIOCYANATO FUNCTIONALIZED METAL COMPLEXES | THE DOW CHEMICAL COMPANY (US) | 1990-07-12 | — | — | WO | disclosed |
| EP-0367223-A2 | Chelants possessing ortho ligating functionality and complexes thereof | THE DOW CHEMICAL COMPANY (US) | 1990-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | TDP1 1370/4885KDM4E 2184/4885LMNA 2305/4885 |
| US-20120045784-A1 | BIOTINIDASE ASSAY | BTD, CMBL, JMJD7 | TDP1 2853/4885KDM4E 466/4885LMNA 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.